Drug intelligence / Profile preview

TRN-005

Development stage: Preclinical
Lead developer: Turn Biotechnologies
Modality: RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
Administration: Unknown (not Specified In Available Sources; Likely Parenteral Or Local Injection Based On Modality But Not Confirmed)

Overview

TRN-005 is an investigational RNA interference (RNAi) therapeutic developed by Turn Biotechnologies. It is designed as a unique formulation to restore muscle mass and strength, specifically targeting age-related conditions such as frailty and sarcopenia that compromise the ability to lead active lifestyles. Preclinical data indicate that TRN-005 improves stem cell growth and differentiation, accelerates muscle recovery, increases muscle fiber thickness and force output, and enhances resistance to subsequent injuries. The drug leverages Turn’s ERA (Epigenetic Reprogramming of Aging) technology platform[1][2][4].

Beyond the preview

Go deeper on TRN-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRN-005.

Explore the full profile